tiprankstipranks
Trending News
More News >
Towa Pharmaceutical Co (TWAPF)
:TWAPF

Towa Pharmaceutical Co (TWAPF) AI Stock Analysis

Compare
1 Followers

Top Page

Towa Pharmaceutical Co (TWAPF) vs. SPDR S&P 500 ETF (SPY)

Towa Pharmaceutical Co Business Overview & Revenue Model

Company DescriptionTowa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of diabetes, digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It had a portfolio of approximately 700 drug products. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.
How the Company Makes Money

Towa Pharmaceutical Co Financial Statement Overview

Summary
Towa Pharmaceutical demonstrates strong revenue growth and profitability margins, indicating robust financial health. However, the company faces challenges with cash flow conversion and maintains a moderate level of leverage. Overall, the financial position appears stable, with opportunities to enhance cash flow efficiency.
Income Statement
78
Positive
Towa Pharmaceutical has shown a strong revenue increase in TTM, with a Gross Profit Margin of 36.2% and Net Profit Margin of 7.6%. The company has successfully improved its EBIT and EBITDA margins compared to previous periods, indicating operational efficiency.
Balance Sheet
70
Positive
The balance sheet reflects a stable but relatively high Debt-to-Equity Ratio of 1.32, suggesting moderate leverage. However, the company maintains a solid Equity Ratio of 36.8%, showing a stable capital structure. ROE is strong at 11.4%, highlighting effective use of equity.
Cash Flow
65
Positive
The operating cash flow to net income ratio is weak due to significant capital expenditures impacting free cash flow. The Free Cash Flow to Net Income Ratio is negative, indicating challenges in converting income into free cash flow despite positive operating cash flow.
Breakdown
TTMMar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Income StatementTotal Revenue
253.35B227.93B208.86B165.62B154.90B110.38B
Gross Profit
91.72B81.38B72.71B70.19B65.45B50.65B
EBIT
23.05B17.65B5.51B19.20B19.92B16.14B
EBITDA
39.82B35.54B24.92B29.49B30.35B24.46B
Net Income Common Stockholders
19.28B16.17B2.20B15.91B13.96B14.50B
Balance SheetCash, Cash Equivalents and Short-Term Investments
30.70B29.65B24.26B32.83B22.91B18.71B
Total Assets
414.69B430.65B371.35B329.94B245.67B228.14B
Total Debt
196.17B202.36B173.06B144.13B84.77B82.39B
Net Debt
165.47B172.71B148.81B111.30B61.85B63.68B
Total Liabilities
265.87B274.76B234.45B197.77B129.07B123.49B
Stockholders Equity
148.82B155.89B136.89B132.17B116.60B104.65B
Cash FlowFree Cash Flow
-16.21B-31.11B-27.93B8.55B2.13B14.49B
Operating Cash Flow
5.70B8.21B2.54B22.13B12.01B19.16B
Investing Cash Flow
-23.87B-40.39B-30.28B-59.73B-9.10B-39.54B
Financing Cash Flow
15.58B35.41B17.48B46.54B184.00M11.75B

Towa Pharmaceutical Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
$1.06B10.0111.38%1.83%
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
$943.41M11.149.44%4.73%
$1.22B15.085.47%2.44%
$1.23B28.254.56%2.13%
73
Outperform
¥78.43B9.42
3.49%8.83%70.61%
69
Neutral
¥174.66B9.49
3.02%-3.69%76.69%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TWAPF
Towa Pharmaceutical Co
25.33
7.41
41.35%
KKPCF
Kaken Pharmaceutical Co
26.44
2.71
11.42%
KSPHF
Kissei Pharmaceutical Co
27.13
6.99
34.71%
TRXPF
Torii Pharmaceutical Co
36.62
13.56
58.80%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,490.00
-144.70
-8.85%
JP:4887
SAWAI GROUP HOLDINGS Co., Ltd.
1,780.00
-107.89
-5.71%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.